TICKERNERD
Menu
VANIVANIHealthcare · Biotechnology

VANI Stock Forecast: Vivani Medical, Inc. Price Predictions for 2026-2027

Last close, 21 Sept 2026
$1.24
+4.20% on the day

The 3 Wall Street analysts covering Vivani Medical, Inc. hold a median 12-month price target of $4 — +222.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 21 Sept 2026 — in the lower half.

Market cap
$111.9M
Ticker Nerd rank
42 / 100
Median analyst target
$4.00
Analysts covering
3
Revenue$0.0
Operating income−$6.9M
Net income−$6.4M
Free cash flow−$6.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.6%
1M
−10.1%
YTD
+0.8%
1Y
−12.1%
From 52W high
−33.7%
From 52W low
+32.2%
$0.94
$1.87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VANI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vivani Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Sept 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
74
Momentum
61
Growth
59
Revisions
53
Issuance
49
Volatility
44
Value
40
Accruals
34
Quality
22

Size (74): Smaller than most of the companies we track.

Quality (22): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VANI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VANI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26VANIHigh $4.00Median $4.00Low $3.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $3.50Median $4.00High $4.00

The green dot is the last close — the median target sits +222.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 June 2026Lake StreetInitiatesBuy$4.00
31 Mar 2026HC Wainwright & Co.MaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
16 Apr 2025HC Wainwright & Co.ReiteratesBuy—
4 Apr 2025HC Wainwright & Co.ReiteratesBuy—
26 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Nov 2024HC Wainwright & Co.InitiatesBuy—
5 Dec 2022ThinkEquityInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VANI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VANI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Sept 2026, Vivani Medical, Inc. returned −12.1% against +17.8% for the S&P 500, dividends included.

VANI vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26VANIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VANI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Vivani Medical, Inc. (VANI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
5.8×

Cheaper than 17% of US stocks

EV / EBITDA
−4.1×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−220.4%

Higher than 7% of US stocks

Return on assets
−48.5%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vivani Medical, Inc. (VANI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vivani Medical, Inc. has a market value of $111.9M and an enterprise value of $109.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$26.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$26.5M.

  • Shares outstanding: 89.4M.

  • Trailing P/E: −2.9×; forward P/E: −3.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Vivani Medical, Inc. employs 42 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Sept 2026

Data provided by Twelve Data

Peers

VANI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VANIVivani Medical, Inc.$111.9M
42
BDTXBlack Diamond Therapeutics, Inc.$111.7M
56
PMVPPMV Pharmaceuticals, Inc.$111.4M
78
MISTMilestone Pharmaceuticals, Inc.$114.3M
17
GNLXGenelux Corp.$114.5M
20
TLSATiziana Life Sciences Ltd. (Bermuda)$116.1M
19
COYACoya Therapeutics, Inc.$116.1M
62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vivani Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VANI news & analysis

Vivani Medical Announces Participation in Upcoming Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

Vivani Medical announced it will participate in two upcoming investor conferences. The company, a clinical-stage biopharmaceutical firm developing miniature, ultra long-acting drug implants using its NanoPortal technology, did not provide further details in the announcement.

Why it matters — Readers following VANI may see the conference appearances as opportunities for the company to engage with investors, though the announcement contains no substantive business or financial updates.

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 13 Aug 2026positive

Vivani Medical reported Q2 2026 financial results, noting all participants were successfully dosed in the Phase 1 trial of NPM-139, a semaglutide implant for weight management, with top-line data expected in November 2026. The company also entered a non-exclusive agreement with Novo Nordisk and anticipates the Cortigent-ClearOne merger completion in Q3 2026.

Why it matters — VANI watchers would care because progress in the NPM-139 clinical trial and the Novo Nordisk agreement represent key milestones for the company's lead pipeline candidate and technology validation.

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

GlobeNewsWire · 6 Aug 2026positive

Vivani Medical announced successful dosing of all participants in SLIM-1, its Phase 1 trial evaluating NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. Dosing of the first participant began ahead of schedule and was rapidly followed by initial dosing across all trial participants.

Why it matters — A VANI watcher would care because completing dosing of all participants marks tangible clinical progress for NPM-139, the company's lead investigational treatment for chronic weight management.

FAQ

Frequently asked questions about VANI stock

What is the VANI stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Vivani Medical, Inc. have a median 12-month price target of $4, with estimates ranging from $3.5 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VANI stock a buy right now?

Of the 3 analysts covering Vivani Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vivani Medical, Inc. 42 out of 100 across roughly 4,600 US stocks as at 21 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VANI?

As at 21 Sept 2026, Vivani Medical, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (74 of 100).

Will VANI stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +222.6% from the last close, and Ticker Nerd's factor model ranks Vivani Medical, Inc. 42 out of 100 as at 21 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VANI stock forecast for 2030?

No analyst covering Vivani Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VANI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $4 over the next 12 months.

How has VANI stock performed over the past year?

Vivani Medical, Inc. returned -12.1% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vivani Medical, Inc. do?

Vivani Medical Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting subdermal drug implants using its proprietary NanoPortal technology.

What is the latest news on VANI?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Vivani Medical Announces Participation in Upcoming Investor Conferences". Vivani Medical announced it will participate in two upcoming investor conferences. The company, a clinical-stage biopharmaceutical firm developing miniature, ultra long-acting drug implants using its NanoPortal technology, did not provide further details in the announcement.

Company

About Vivani Medical, Inc.

Vivani Medical Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting subdermal drug implants using its proprietary NanoPortal technology. The company’s current work centers on implant-based therapies designed to deliver medicines steadily over extended periods, with an emphasis on improving medication adherence and tolerability in chronic diseases. Its product pipeline includes GLP-1-based implants under development for obesity, chronic weight management, and type 2 diabetes, reflecting a focus on metabolic health applications. Vivani Medical also operates a neuromodulation segment, broadening its presence in advanced implantable medical technologies. Headquartered in Alameda, California, the company plays a specialized role in the drug-delivery market by addressing challenges associated with frequent oral or injectable dosing through long-duration implant solutions.

CEO Dr. Adam Mendelsohn Ph.D. · 42 employees · United States · https://www.vivani.com